Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.97 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ESRRG | P62508 | 3/20 | 0.97 |
| ▸ | PGR | P06401 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | NPC1 | O15118 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL4323848 | 1.00 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL119181 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL5789295 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17629799 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118119606-A | Cyclic peroxides as prodrugs for drug selective delivery | 加利福尼亚大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| CN-114341159-B | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117916596-A | Method for analyzing target molecules in biological fluid | 格里尔公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117642168-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117460714-A | PCNA inhibitors and EGFR inhibitors for cancer treatment | 希望之城 | 2024-01-26 | — | — | CN | disclosed |
| CN-116940378-A | Treatment of neuroendocrine cancer | 加利福尼亚大学董事会 | 2023-10-24 | — | — | CN | disclosed |
| CN-116710429-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-09-05 | — | — | CN | disclosed |
| CN-116583276-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-08-11 | — | — | CN | disclosed |
| CN-109789146-B | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115916226-A | Oncolytic viral compositions and methods for treating cancer | 希望之城 | 2023-04-04 | — | — | CN | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| CN-1809383-A | Recombinant IL-9 antibodies and uses thereof | MEDIMMUNE INC (US) | 2006-07-26 | — | — | CN | disclosed |
| CN-1780850-A | Use of lectins to promote oligomerization of glycoproteins and antigenic molecules | ANTIGENICS INC (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6410587-B1 | FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS | NEORX CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| CN-1184123-A | Organic optical component | MITSUI TOATSU CHEMICALS (JP) | 1998-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | ESR1 3747/4885ESR2 596/4885MAPT 2471/4885 |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | ESR1 3747/4885ESR2 596/4885MAPT 2471/4885 |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | ESR1 3747/4885ESR2 596/4885MAPT 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.